Perioperative treatment strategies in EGFR-mutant early-stage NSCLC: current evidence and future challenges
Abstract Treatment with 3-year of adjuvant osimertinib is considered a new standard in
patients with completely resected stage I-IIIA non-small cell lung cancer (NSCLC) harboring …
patients with completely resected stage I-IIIA non-small cell lung cancer (NSCLC) harboring …
[HTML][HTML] Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma
JS Lee, EK Kim, KA Kim, HS Shim - Cancer Research and …, 2024 - ncbi.nlm.nih.gov
Purpose We investigated the clinical impact of genomic and pathway alterations in stage I
epidermal growth factor receptor (EGFR)–mutant lung adenocarcinomas, which have a high …
epidermal growth factor receptor (EGFR)–mutant lung adenocarcinomas, which have a high …
Flexible and Highly-Efficient Feature Perception for Molecular Traits Prediction via Self-interactive Deep Learning
Predicting disease-related molecular traits from histomorphology brings great opportunities
for precision medicine. Despite the rich information present in histopathological images …
for precision medicine. Despite the rich information present in histopathological images …
Differential Prognostic Value of Vascular Invasion in Resected Lung Adenocarcinomas According to Epidermal Growth Factor Receptor Mutational Status
Background It is unclear whether all patients with stage IB to IIIA epidermal growth factor
receptor (EGFR)-mutant adenocarcinoma should receive adjuvant osimertinib. We …
receptor (EGFR)-mutant adenocarcinoma should receive adjuvant osimertinib. We …
Clinicopathologic and Molecular Subtyping of EGFR Mutation—Response
HA Jung, J Lim, YL Choi, J Kim, K Park - Clinical Cancer Research, 2023 - AACR
We appreciate the comments from S. Sorscher regarding our recently published
article,“Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage …
article,“Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage …
Clinicopathologic and Molecular Subtyping of EGFR Mutation
S Sorscher - Clinical Cancer Research, 2023 - AACR
Jung and colleagues found that among patients with EGFR-mutated non–small cell lung
cancer (NSCLC), patients with tumor molecular profiles that also demonstrated a TP53 …
cancer (NSCLC), patients with tumor molecular profiles that also demonstrated a TP53 …
[HTML][HTML] ADAURA: redefining the role of target therapy in resectable lung adenocarcinoma
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers
(LCs)(1). The prevalence of lung adenocarcinoma (LUAD) has decreased significantly …
(LCs)(1). The prevalence of lung adenocarcinoma (LUAD) has decreased significantly …
CHEK2 Pathogenic Germline Variants in Patients With NSCLC
S Sorscher - JTO Clinical and Research Reports, 2022 - jtocrr.org
To the Editor: Zhang et al. 1 recently reported that among 70 patients with NSCLC who
carried CHEK2 pathogenic germline variants (PGVs), 29 (41.4%) had tumor “potentially …
carried CHEK2 pathogenic germline variants (PGVs), 29 (41.4%) had tumor “potentially …